Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CENPE | Q02224 | 3/20 | 0.49 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 8/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3229438 | 1.00 | CENPE (0.49) | CENPEKIFC1DHODHPDK1PDK2 | |
| SCHEMBL3230216 | 0.93 | CENPE (0.49) | CENPEKIFC1DHODHPDK1PDK2 | |
| SCHEMBL3222007 | 0.93 | CENPE (0.49) | CENPEKIFC1DHODHPDK1PDK2 | |
| SCHEMBL3222019 | 0.93 | CENPE (0.49) | CENPEKIFC1DHODHPDK1PDK2 | |
| SCHEMBL3230227 | 0.93 | CENPE (0.49) | CENPEKIFC1DHODHPDK1PDK2 | |
| SCHEMBL3233280 | 0.92 | CENPE (0.59) | CENPEKIFC1DHODHPDK1PDK2 | |
| SCHEMBL3233756 | 0.91 | CENPE (0.47) | CENPEKIFC1DHODHS1PR1 | |
| SCHEMBL3233612 | 0.89 | CENPE (0.44) | CENPEKIFC1DHODHPDK1PDK2 | |
| SCHEMBL3221828 | 0.88 | CENPE (0.46) | CENPEKIFC1DHODH | |
| SCHEMBL13625028 | 0.88 | CENPE (0.46) | CENPEKIFC1DHODHPDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069453-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2010-03-18 | — | — | US | claimed |
| EP-1951719-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2008-08-06 | — | — | EP | claimed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | claimed |
| WO-2007056469-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | claimed |
| US-20100069453-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2010-03-18 | — | — | US | disclosed |
| US-7582668-B2 | Imidazoyl-benzamide anti-cancer agents | CYTOKINETICS, INCORPORATED (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069453-A1 | Certain Chemical Entities, Compositions, and Methods | KIF5B, KIF2C, PLK1 | CENPE 54/4885KIFC1 4/4885DHODH 1141/4885 |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CENPE 54/4885KIFC1 4/4885DHODH 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.